We serve Chemical Name:2,4-dioxo-1,3-diazinane-5-carboxylic acid CAS:92264-75-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,4-dioxo-1,3-diazinane-5-carboxylic acid
CAS.NO:92264-75-0
Synonyms:2,4-Dioxo-hexahydro-pyrimidin-5-carbonsaeure;2,4-DIOXOHEXAHYDROPYRIMIDINE-5-CARBOXYLIC ACID
Molecular Formula:C5H6N2O4
Molecular Weight:158.11200
HS Code:
Physical and Chemical Properties:
Melting point:255-256ºC
Boiling point:N/A
Density:1.523
Index of Refraction:
PSA:95.50000
Exact Mass:158.03300
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2,4-Dioxo-hexahydro-pyrimidin-5-carbonsaeure chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-DIOXOHEXAHYDROPYRIMIDINE-5-CARBOXYLIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-DIOXOHEXAHYDROPYRIMIDINE-5-CARBOXYLIC ACID Use and application,2,4-DIOXOHEXAHYDROPYRIMIDINE-5-CARBOXYLIC ACID technical grade,usp/ep/jp grade.
Related News: No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel. 2,4-dioxo-1,3-diazinane-5-carboxylic acid manufacturer Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology. 2,4-dioxo-1,3-diazinane-5-carboxylic acid supplier The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 2,4-dioxo-1,3-diazinane-5-carboxylic acid vendor No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel. 2,4-dioxo-1,3-diazinane-5-carboxylic acid factory The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward.
